Lu Peng 4

What Happened
Lu Peng, Chief Medical Officer of Pharvaris N.V., exercised stock options on April 29–30, 2026 to acquire 18,733 shares (3,733 on 4/29 and 15,000 on 4/30) at $2.59 per share, paying about $48,518 in exercise costs. Those shares were sold under a Rule 10b5‑1 plan on the same dates: 3,733 shares sold on 4/29 for a weighted average price of $30.06 (proceeds $112,232) and 15,000 shares sold on 4/30 for a weighted average price of $30.24 (proceeds $453,627). Total sale proceeds were roughly $565,859. The transactions appear to be a standard exercise followed by immediate sale (effectively a cashless exercise) executed under a pre‑arranged 10b5‑1 plan.

Key Details

• Transaction dates: April 29, 2026 (3,733 shares) and April 30, 2026 (15,000 shares).
• Exercise price paid: $2.59 per share; total paid ≈ $48,518.
• Sales: weighted average prices $30.06 (4/29) and $30.24 (4/30); total proceeds ≈ $565,859.
• Footnotes: F1 confirms these were scheduled transactions under a Rule 10b5‑1 plan; F2/F3 note sales were executed at multiple prices and the filing gives weighted averages; F4 describes vesting schedule of the option grant; F5 corrects previously reported option counts (no new transaction).
• Shares/derivatives owned after the transactions: the filing updates the number of derivative securities held (F5); consult the full Form 4 for the exact post‑transaction beneficial ownership.
• Timeliness: Form 4 filed 2026‑05‑01 for transactions on 4/29–4/30 (filed within the normal 2‑business‑day window).

Context
This is a routine insider exercise-and-sell executed under a prearranged 10b5‑1 plan. Such transactions generally reflect planned liquidity rather than an explicit signal about company prospects. Because the shares were exercised and then sold immediately, this functions like a cashless exercise rather than a long‑term purchase.